Adlai Nortye Ltd. (ANL) Key Statistics & Financial Ratios

Adlai Nortye Ltd. (ANL) — Price $15.52 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Adlai Nortye Ltd. (ANL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.

Stock Data

Price$15.52
Market Cap$824M
Enterprise Value$717.9M
Beta-0.65
ExchangeNASDAQ
CountrySG

Valuation Multiples

P/E Ratio-7.75
Price / Book1.12
P/S40.86
EV/EBITDA-33.44
EV/Sales36.48
EV/FCF-12.32
P/FCF-13.80
Earnings Yield-9.12%
FCF Yield-7.07%
Dividend Yield0.00%

Profitability

Gross Margin100.00%
EBIT Margin-113.28%
EBITDA Margin-109.09%
Operating Margin-113.28%
Net Margin-114.48%
Return on Equity-21.82%
Return on Assets-9.07%
Return on Invested Capital-9.23%
Return on Capital Employed-9.99%

Financial Health

Current Ratio9.55
Quick Ratio9.55
Cash Ratio5.26
Debt / Equity0.12
Debt / Assets10.75%
Net Debt / EBITDA4.93
Interest Coverage-16.99

Per-Share Data

Revenue per share1.24
Book Value per share13.49
Cash per share14.56
FCF per share-3.66
Tangible Book Value per share13.49
Dividend per share0.00

Related companies: ADAP · ADTX · AIMD · APLM · BLRX · GOVX · ICU

Explore sector: Healthcare · Biotechnology

More sections of ANL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks